)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Aclaris Therapeutics
Aclaris Therapeutics (ACRS) investor relations material
Aclaris Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 revenue was $1.481M and net loss was $18.510M; 9M revenue was $5.106M and net loss was $59.839M, with higher R&D expense contributing to wider losses.
ATI-052 reported positive Phase 1b results in atopic dermatitis and asthma; bosakitug Phase 2 top-line results and other pipeline milestones are expected in Q4 2026.
Cash, cash equivalents and marketable securities totaled $204.607M at quarter-end; October financing generated $46.7M net proceeds.
Financial highlights
Q3 revenue was $1.481M vs. $3.299M YoY; 9M revenue was $5.106M vs. $6.531M, primarily reflecting a prior-year Sun Pharma sales milestone.
Q3 net loss was $18.510M vs. $14.614M; 9M net loss was $59.839M vs. $45.128M. Operating loss was $21.344M in Q3 and $67.774M for 9M.
Q3 R&D expense was $16.066M vs. $13.028M; 9M R&D expense was $49.789M vs. $36.061M, mainly reflecting ATI-052 and ATI-9494 development and manufacturing costs.
9M net cash used in operating activities was $62.076M vs. $33.982M, reflecting higher adjusted net losses and lower cash received from operating assets.
Outlook and guidance
Top-line results from the 109-patient Phase 2 ADMIRATION trial of bosakitug in moderate-to-severe atopic dermatitis are expected in Q4 2026.
Modzatinib Phase 2b in lichen planus is expected to initiate in Q4 2026; first site activation was expected in November.
ATI-9494 IND filing remains on track for Q4 2026.
ATI-052 is initially prioritized for a Phase 2b EoE trial planned for early 2027; selection of an additional Phase 2b indication is expected shortly.
Following the October offering, available cash and securities are expected to fund operations through H1 2029, excluding potential business development or additional financing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aclaris Therapeutics
- ATI-052 showed AD and asthma activity; next-stage development will prioritize EoE.ACRS
Study result - Multiple late-stage readouts and new trials in I&I set the stage for significant pipeline progress.ACRS12th Annual Cantor Fitzgerald Global Healthcare Conference
- Net loss rose to $41.3M as R&D spending increased, with $170.6M liquidity and major clinical milestones ahead.ACRSQ2 2026
- Advancing TSLP biologics and ITK/JAK3 inhibitors with late 2026 clinical catalysts expected.ACRSGuggenheim Securities Emerging Outlook: Biotech Summit 2026
- Key bispecific and TSLP mAb data readouts expected in H2, with phase II asthma trial starting Q4.ACRSJefferies Global Healthcare Conference 2026
- All proposals passed, with board elections, compensation, and auditor ratification approved.ACRSAGM 2026
- Multiple late-stage immunology assets advance toward key 2024 and 2026 milestones, backed by strong funding.ACRSBank of America Global Healthcare Conference 2026
- Lead assets show strong efficacy and safety in large immune disease markets, with cash runway to 2028.ACRSCorporate presentation
- ATI-052 offers best-in-class potency, long dosing intervals, and strong early efficacy data.ACRSH.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Next Aclaris Therapeutics earnings date
Guggenheim 3rd Annual Healthcare Innovation Conference9 Nov, 2026
Aclaris Therapeutics
Next Aclaris Therapeutics earnings date
Guggenheim 3rd Annual Healthcare Innovation Conference9 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Aclaris Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily engaged in the development of novel drug candidates for immuno-inflammatory diseases. Leveraging its core expertise in drug discovery, development, and kinase inhibition, Aclaris focuses on creating small molecule therapies for people affected by underserved immuno-inflammatory conditions. Its proprietary KINect® technology platform enables the development of clinical candidates targeting challenging kinases with novel approaches. Additionally, Aclaris operates Confluence Discovery Technologies, Inc., a full-service drug discovery and early development contract research organization. This subsidiary offers research partnership services across therapeutic areas and gene families, with expertise in a range of scientific disciplines including cell and molecular biology, biochemistry, enzymology, and immunology. he company is headquartered in Wayne, Pennsylvania, and its shares are listed on the Nasdaq.